Recursion Pharmaceuticals Phase 2 Shows 47% Median Polyp Burden Reduction
The Phase 2 update also says 85% of evaluable patients were below baseline after 12 weeks off treatment.
The Phase 2 update also says 85% of evaluable patients were below baseline after 12 weeks off treatment.